Evidence map›Paper›PMID 42275218›Full record

ArticleCell reports2026

Amplification of MED30 at chromosome 8q24 reprograms MYC binding to low-affinity oncogenic enhancers in cancer cells.

Chunyu Jin, Linjie Zhao, Wubin Ma, Guofeng Zhao, Yujia Liu, Hanwen Zhang, Shenghong Ma, Likun Yao, Yuan Liu, Qiulian Wu and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Chunyu JinDepartment and School of Medicine, San Diego, La Jolla, CA, USA. Electronic address: c3jin@ucsd.edu.
Linjie ZhaoUPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Wubin MaDepartment and School of Medicine, San Diego, La Jolla, CA, USA.
Guofeng ZhaoDepartment and School of Medicine, San Diego, La Jolla, CA, USA.
Yujia LiuDepartment and School of Medicine, San Diego, La Jolla, CA, USA.
Hanwen ZhangDepartment and School of Medicine, San Diego, La Jolla, CA, USA.
Shenghong MaDepartment of Pharmacology and Moores Cancer Center, San Diego, La Jolla, CA, USA.
Likun YaoDepartment and School of Medicine, San Diego, La Jolla, CA, USA.
Yuan LiuDepartment of Bioengineering, University of California, San Diego, La Jolla, CA, USA.
Qiulian WuUPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Huairui YuanUPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Kailin YangDepartment of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.
Wei YuanDepartment and School of Medicine, San Diego, La Jolla, CA, USA.
Kenneth OhgiDepartment and School of Medicine, San Diego, La Jolla, CA, USA.
Jeremy N RichUPMC Hillman Cancer Center, Pittsburgh, PA, USA; Department of Neurology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Electronic address: drjeremyrich@gmail.com.
Michael G RosenfeldDepartment and School of Medicine, San Diego, La Jolla, CA, USA. Electronic address: mrosefeld@ucsd.edu.

Funding

HORMONAL AND DEVELOPMENTAL REGULATION OF GENE EXPRESSIONR01DK018477 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROSENFELD, MICHAEL G · 1986 to 2025
$12.7M
REGULATION OF NEUROENDOCRINE SWITCHING EVENTSR37DK039949 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROSENFELD, MICHAEL G · 1987 to 2020
$12.3M
Dynamic Complexity of Brain Tumor Stem Cells (R35CA197718)R35CA197718 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RICH, JEREMY N · 2015 to 2021
$6.4M
Metabolic Regulation of Glioblastoma EpitranscriptomicsR01CA268634 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Sameer Agnihotri, JEREMY N RICH · 2022 to 2026
$2.9M
Targeting the Circadian Rhythm in Glioblastoma Stem Cells (R01CA238662)R01CA238662 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAY, STEVE A, RICH, JEREMY N · 2020 to 2024
$2.8M
A stress-induced promoter pause release program in cardiomyocytes protecting against myocardial infarctionR01HL150521 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROSENFELD, MICHAEL G · 2020 to 2023
$2.7M
REGULATION OF NEUROENDOCRINE SWITCHING EVENTSR01DK039949 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROSENFELD, MICHAEL G · 1996 to 2024
$2.4M
Viral IncRNAs Regulate Host Genomic Transcriptional Programs Associated with Sporadic Alzheimer's DiseaseR01AG074307 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MICHAEL G ROSENFELD · 2022 to 2026
$2.0M
Dual Targeting of Brain Tumor Initiating Cells through Inhibition of BMI1 and EZH2 (R01NS103434)R01NS103434 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RICH, JEREMY N · 2017 to 2021
$1.7M
Illumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600k
Phase Separation-involved Roles of Mediator Complex in Myc-amplified CancerK22CA255404 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JIN, CHUNYU · 2022 to 2024
$557k
NCI NIH HHS K22 CA255404NCI NIH HHS R01 CA238662NCI NIH HHS R01 CA268634NCI NIH HHS R35 CA197718NHLBI NIH HHS R01 HL150521NIA NIH HHS R01 AG074307NIDDK NIH HHS R01 DK018477NIDDK NIH HHS R01 DK039949NIDDK NIH HHS R37 DK039949NIH HHS S10 OD026929NINDS NIH HHS R01 NS103434
6 · The paper itself

Abstract

The activity of many oncogenic transcription factors (TFs) is constrained by enhancer binding-site affinity, leaving many low-affinity sites unoccupied under physiological conditions. Whether coactivator amplification in cancer redirects TFs to these sites is unclear. Here, we show that amplification of MED30, a Mediator subunit at 8q24, promotes aberrant MYC binding to low-affinity regulatory regions and is associated with poor outcomes. Besides frequent MYC MED30 co-amplification, MED30 overexpression alone is sufficient to enable MYC occupancy and activation of previously weak or unbound enhancers and promoters, driving tumor-promoting gene expression. Functional studies in pancreatic ductal adenocarcinoma and glioblastoma demonstrate that MED30 is oncogenic and serves as a prognostic marker independent of MYC amplification. These findings reveal a cofactor-driven mechanism by which MED30 licenses MYC binding to low-affinity sites, reprogramming enhancers during cancer progression with therapeutic implications.

Indexed as

Chromosomes, Human, Pair 8Enhancer Elements, GeneticGene AmplificationMediator ComplexProto-Oncogene Proteins c-mycAnimalsBinding SitesCell Line, TumorGene Expression Regulation, NeoplasticHumansPancreatic NeoplasmsPromoter Regions, GeneticProtein BindingMediator ComplexProto-Oncogene Proteins c-mycCP: cancerCP: molecular biologyCUT&Tagenhancer activationgene amplificationglioblastomalow-affinity binding sitesMED30mediator complexMYCpancreatic cancertranscriptional program

Identifiers

PMID42275218
PMCPMC13384758

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.